Healthcare / Elderly CareChina
← Sticker Wall
JOURNEY · DETAIL
Mindray's Li Xiting: From Agency Start to Becoming China's Medical Device Giant Breaking Foreign Monopoly
Founded: Li Xiting, Xu Hang, Cheng Minghe · Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionChina
ScaleGiant
ChannelOther
Origin
In 1991, Li Xiting, Xu Hang, and Cheng Minghe, who had backgrounds at the Acoustics Institute of the Chinese Academy of Sciences, founded Mindray in Shenzhen. At that time, equipment such as patient monitors and ventilators in Chinese hospitals was almost entirely monopolized by foreign brands like GE, Philips, and Siemens, featuring high prices and long maintenance wait times. The trio initially accumulated capital by acting as agents for foreign medical devices. After making their first pot of gold, they decided to pursue self-research, reasoning that agency business lacks pricing power and technological barriers, and that they could only survive by creating China's own patient monitors.
Milestones
1991
Inception Failure
In 1991, Mindray was founded in Shenzhen, surviving on profit margins from acting as an agent for foreign monitoring and ultrasound equipment from brands like GE. However, agency profits were thin and authorizations could be revoked by manufacturers at any time. Facing financial pressure, the team initiated self-research on patient monitors in 1992. After its launch, the first PM 9000 pulse oximetry monitor lacked brand recognition and could only break into county and municipal hospitals at less than half the price of foreign equivalents. This phase lasted from 1991 to 1992.
1998
Expansion Turning Point
Around 1998, Mindray expanded its product line from patient monitors to hematology analyzers and ultrasound equipment. Self-research expenses far exceeded agency income, and the company temporarily relied on venture capital funding from firms like Walden International to stay afloat. Around 2000, it gradually established a solid foothold in the domestic mid-range monitor market, validating a product-market fit path centered on high cost-performance entering public hospitals. This phase lasted from 1998 to 2000.
2006
IPO Growth
In 2006, Mindray Medical went public on the New York Stock Exchange, becoming the first overseas-listed company in China's medical device industry. Funds raised were used for R&D and international layout. Annual revenue at the time had already surpassed the 1 billion RMB mark. The Shenzhen engineer dividend, combined with a pricing system 30 percent lower than foreign competitors, allowed Mindray to enter the European market on a large scale.
2008
M&A Inflection Point
During the 2008 financial crisis, Mindray acquired the patient monitoring business of Datascope, a veteran US patient monitoring manufacturer, for approximately 209 million USD, directly acquiring its installed hospital channels and high-end brand recognition in Europe and the US. This acquisition, initially doubted as a 'snake swallowing an elephant,' was later regarded as one of the most successful outbound M&A deals in the Chinese medical device sector, significantly boosting its overseas revenue proportion.
2016
Delisting from US Turning Point
In 2016, Mindray privatized and delisted from the NYSE at a valuation of approximately 3.3 billion USD. Core reasons included US stock valuations remaining lower than domestic peers for extended periods, and Chinese concept stocks facing valuation suppression from short-sellers. The privatization saddled the company with massive debt, viewed internally as a high-stakes gamble wagering that a return to the A-share market would secure valuations matching its leading industry status.
2018
A-Share IPO Growth
In 2018, Mindray listed on the ChiNext board of the Shenzhen Stock Exchange. Post-listing, its market capitalization briefly surpassed 600 billion RMB, making it the top player in A-share medical devices. During the pandemic from 2019 to 2022, global sales of ventilators and monitors surged. In 2021, revenue reached 25.27 billion RMB with net profits of approximately 8 billion RMB, propelling founder Li Xiting into the upper ranks of China's wealthy list.
2024
Pressure Failure
Starting in 2024, the confluence of domestic medical anti-corruption campaigns, equipment VBP, and tightening fiscal procurement caused Mindray's domestic business growth to plummet. In 2025, the company experienced its first-ever year-on-year decline in both revenue and profit since listing, with market capitalization shrinking by about 300 billion RMB from its peak. Among Mindray's trio of founders, Xu Hang and Cheng Minghe stepped back, leaving 75-year-old Li Xiting to steer the ship alone through the trough. This phase lasted from 2024 to 2025.
2025
Re-globalization Inflection Point
From late 2025 to 2026, Mindray advanced a Hong Kong IPO to establish an A+H dual-financing platform, extending its five-year commitment into a ten-year long-term investment. Overseas revenue reached approximately 17.6 billion RMB, with its share of total revenue steadily increasing. The company focused heavily on high-end hospital monitoring, anesthesia, and minimally invasive surgical equipment in Europe and the US, attempting to hedge against the long-term suppression of domestic VBP with overseas growth. This phase lasted from 2025 to 2026.
Turning Points
- The 2008 acquisition of Datascope's monitoring business, exchanging 209 million USD for high-end hospital channels in Europe and the US, marked the watershed moment from low-priced volume strategies to global branding.
- The 2016 privatization and delisting from the NYSE carrying massive debt was a high-stakes gamble wagering on a valuation recovery in the A-share market, which ultimately paid off.
- Following 2024, domestic VBP and anti-corruption campaigns caused declines in both revenue and profit, prompting the company to shift its main battlefield to overseas high-end markets and advance a Hong Kong IPO.
Failures & Pitfalls
- Early self-developed monitors lacked brand recognition, forcing the company to struggle into county and municipal hospitals at less than half the price of foreign brands with razor-thin profits for years.
- For ten years after its NYSE listing, valuations were continuously suppressed by capital markets that did not recognize the pricing power of Chinese medical device companies, forcing a privatization delisting.
- After the pandemic dividend faded, domestic VBP and medical anti-corruption initiatives triggered the first-ever revenue and profit decline since listing between 2024 and 2025, evaporating about 300 billion RMB in market value.
关键成功要素
- Prioritizing foreign agency work to generate cash flow before pouring profits into self-research, using agency revenue to incubate the first domestic patient monitor production line.
- Sustaining high R&D intensity at roughly 10% of revenue year after year, leveraging the engineer dividend to drive high-end equipment costs below 70% of foreign alternatives.
- Executing counter-cyclical M&A of Datascope during the financial crisis, trading capital for channels and licenses to shorten market entry times in Europe and the US by a decade.
- Building a capillary-like sales network domestically by sinking channels down to county hospitals, and then leveraging China's massive supply chain scale to wage a global price war.
- Founders maintaining a wartime posture with long stays at company bases, where 75-year-old Li Xiting still personally presides over major product reviews.
Lessons
- In highly regulated and high-barrier industries, money earned from agency businesses must be rapidly converted into independent technologies and registration certificates, or distribution channels risk being severed by upstream partners at any time.
- Entering high-end markets cannot rely solely on low prices; acquiring mature brands and channels is the fastest path to shortening trust cycles, though integration failure rates are extremely high and targets require careful selection.
- Policy is the industry's largest variable; the ventilator myth created by the pandemic and the revenue/profit declines caused by VBP both demonstrate that betting a destiny on a single policy dividend is unsustainable.
- Valuation mismatch itself can become a strategic weapon; privatization and returning to A-shares show that entrepreneurs must proactively choose capital markets that understand them.
- The second half of going global relies not on product pricing, but on local service and clinical evidence, which will determine whether Li Xiting's ten-year commitment can be fulfilled.
Core Data
- 2024年营收：36.73 billion RMB (based on public data disclosures, independent review not verified)
- 2021年营收：25.27 billion RMB (based on public data disclosures, independent review not verified)
- 海外营收规模：Approximately 17.6 billion RMB (based on public data disclosures, independent review not verified)
- 2021年市值高点：Approximately 600 billion RMB (based on public data disclosures, independent review not verified)
- 研发投入占比：Consistently around 10% (based on public data disclosures, independent review not verified)
- Datascope并购金额：Approximately 209 million USD (based on public data disclosures, independent review not verified)
- 2025年市值缩水：Approximately 300 billion RMB down from peak (based on public data disclosures, independent review not verified)
Competitors / Peers
In the global market, Mindray benchmarks against the GPS foreign trio (GE Healthcare, Philips, and Siemens Healthineers), competing head-on in monitoring and anesthesia, while benchmarking against Medtronic and Johnson & Johnson Medical in minimally invasive surgery. Domestic peers include United Imaging Healthcare in high-end imaging equipment breakthroughs, Yuyue Medical in home medical devices, MicroPort Scientific in interventional cardiology consumables, and Mindray's competitors in rigid endoscopes such as Shenzhen Mindray (or EDAN Instruments / Kindly / Aohua Endoscopy). Mindray's unique position lies in spanning three major tracks: life information and support, in-vitro diagnostics, and medical imaging, making it one of the few Chinese companies capable of competing simultaneously with foreign giants across multiple product lines.